The Center for Biosimilars recaps the top 5 biosimilars articles for the week of February 19, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of February 19.
Number 5: A white paper from the Association for Accessible Medicines says that brand-name drug products are behind high prescription drug costs, and that those high costs endanger patients’ health.
Number 4: At last week’s 13th annual congress of the European Crohn's and Colitis Organisation, researchers presented findings from several studies investigating the efficacy of 2 biosimilar infliximab products.
Number 3: Investigators have released data from a 26-week open label extension of the NOR-SWITCH trial in patients with inflammatory bowel disease.
Number 2: The Patients for Biologic Safety and Access, a patient advocacy group, called on the FDA to revise its materials on biosimilars. However, some patient groups are calling PBSA’s stance into question.
Number 1: Express Scripts and Walgreens Boots are expanding their purchasing efforts to include specialty medications, such as biologics and biosimilars.
Also this week, contributor Amanda Forys, of Xcenda, explained what biosimilar manufacturers need to know about changes to the 340B Drug Pricing Program.
Finally, last week, our e-newsletter asked for your thoughts on when nonmedical substitution will become a reality in the United States.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.